Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries
Myriad Genetics Inc
(NQ:
MYGN
)
30.10
USD
+1.07 (+3.69%)
Official Closing Price
Updated: 4:33 PM EST, Feb 24, 2021
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
783,900
Open
28.41
Bid (Size)
25.00 (1)
Ask (Size)
32.00 (1)
Prev. Close
29.03
Today's Range
27.52 - 31.29
52wk Range
9.240 - 31.59
Shares Outstanding
69,906,818
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
Top News
More News
Myriad Genetics Delivers 6% Sequential Revenue Growth; Company Continues to Execute Strategic Transformation Plan
February 23, 2021
From
GlobeNewswire News Releases
Technology and Health Leaders Join Myriad Genetics, Advance in Senior Roles to Drive Key Enterprise Functions, Transformation and Growth Initiatives
February 18, 2021
New talent and promotions span core businesses, transformation, IT, revenue cycle management, business development, marketing, legal
From
GlobeNewswire News Releases
Performance
YTD
+51.10%
+51.10%
1 Month
+13.37%
+13.37%
3 Month
+65.29%
+65.29%
6 Month
+112.72%
+112.72%
1 Year
+67.32%
+67.32%
More News
Read More
Myriad Genetics to Announce December 2020 Quarterly Financial Results on February 23, 2021
February 16, 2021
From
GlobeNewswire News Releases
New Study from Leading University of Utah Radiation Oncologist Validates Ability of Myriad Genetics’ Prolaris® test to Guide Treatment for Prostate Cancer
February 12, 2021
From
GlobeNewswire News Releases
Myriad Genetics to Participate in Multiple Upcoming Health and Technology Conferences
February 11, 2021
From
GlobeNewswire News Releases
GeneSight Psychotropic Test’s Combinatorial Approach Proves Better than Single-Gene Testing at Predicting Patient Outcomes and Medication Blood Levels
February 08, 2021
From
GlobeNewswire News Releases
Myriad Genetics Launches New Vectra® Cardiovascular Risk Assessment for Patients with Rheumatoid Arthritis
February 02, 2021
From
GlobeNewswire News Releases
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Myriad Genetics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
January 18, 2021
From
PR Newswire
Myriad Genetics Forms Strategic Partnership with Illumina in Oncology
January 11, 2021
From
GlobeNewswire News Releases
Recap: Myriad Genetics Q2 Earnings
February 23, 2021
Tags
Market News
Benzinga
Earnings
From
Benzinga
Myriad Genetics Provides Transformation Update, Pursues Strategic Alternatives for Autoimmune Business, Realigns International Operations
January 05, 2021
From
GlobeNewswire News Releases
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.